IsoRay completes Cs-131 brachytherapy seeds feasibility study for breast cancer treatment

October 21, 2015

Radiation is one of the most important and potent weapons used in treating cancers. Brachytherapy is internal radiation therapy in which radioactive material (isotopes) is used to kill cancer cells. IsoRay's patented Cs-131 brachytherapy seeds represent the biggest advancement in internal radiation therapy in twenty years providing several advantages over other internal radiation therapies. Doctors can vigorously treat a variety of cancers limiting the damage to healthy surrounding tissues and organs compared to other radiation therapies.

IsoRay CEO Dwight Babcock says he is optimistic about IsoRay's future progress. "We believe this new application of Cesium-131 will have a significant impact on breast cancer and improve the quality of life for many women who are struggling with this devastating disease. It is extremely fitting that we are able to reveal this important development during Breast Cancer Awareness Month. I have high expectations for the treatment's availability in 2011," he said. Babcock went on to discuss IsoRay's implementation of its strategic plan. He explained that IsoRay is aggressively pursuing its plan to advance the adoption and usage of its revolutionary internal radiation therapy to treat cancers throughout the body.

With established CMS codes, Cesium-131 is FDA-cleared for use in the treatment of cancers throughout the body including breast cancer. More than 100 centers across the country are using Cesium-131 to treat brain, colon, head and neck, lung, ocular melanoma, and prostate cancers.

Source: IsoRay, Inc.